Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

Table 3 Improved OA Pain Intensity and Patient's and Physician's Global Assessments of Disease Activity (ITT Population)

	Lumiracoxib 100 mg o.d. (n = 755)	Lumiracoxib 100 mg b.i.d. (n = 1,519)	Celecoxib 200 mg o.d. (n = 758)
Patient's target joint pain intensity assessment
Changes in scores from baseline to study endpoint, n (%)^†
Improvement	382 (50.6)	795 (52.3)	406 (53.6)
No change	269 (35.6)	566 (37.3)	265 (35.0)
Worsened	104 (13.8)	158 (10.4)	87 (11.5)
Overall measure of efficacy, least squares mean^‡	2.78	2.72	2.77
Patient's global assessment of disease activity
Changes in scores from baseline to study endpoint, n (%)^†
Improvement	368 (48.7)	768 (50.6)	373 (49.2)
No change	265 (35.1)	534 (35.2)	269 (35.5)
Worsened	122 (16.2)	216 (14.2)	116 (15.3)
Overall measure of efficacy, least squares mean^‡	2.61	2.54	2.60
Physician's global assessment of disease activity
Changes in scores from baseline to study endpoint, n (%)^†
Improvement	411 (54.5)	888 (58.5)	425 (56.2)
No change	244 (32.4)	463 (30.5)	232 (30.7)
Worsened	99 (13.1)	167 (11.0)	99 (13.1)
Overall measure of efficacy, least squares mean^‡	2.55	2.45*	2.52

o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat; ^†patients with missing baseline values were not included; ^‡Overall measure of efficacy defined as the weighted average of post-baseline scores using the last observation carried forward technique for missing values and time since previous visit as weight (lower scores represent better responses); *p < 0.05 vs lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.

ISSN: 1471-2474